ArticleScientific reports2017
Establishing zebrafish as a model to study the anxiolytic effects of scopolamine.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 112 citations in OpenAlex.
- Chronic Administration of Carvone-RichPlants (Basel, Switzerland) · 2026Article
- Behavioral, Biochemical, andPharmaceuticals (Basel, Switzerland) · 2026Article
- Melissa officinalis essential oil modulates oxidative balance, cholinergic activity, and cognitive performance in a scopolamine-induced zebrafish model: implications for neuroprotective strategies in cognitive disorders.Scientific reports · 2025Article
- Mechanisms Underlying the Cognitive Benefits ofPlants (Basel, Switzerland) · 2025Article
- Pyrimidine Derivative, (E)-N-[4-(4-Chlorophenyl)-6-(4-Methylphenyl)Pyrimidin-2-yl]-1-(Furan-2-yl)Methanimine, Named BN5 Ameliorates Cognitive Dysfunction and Regulates esr1 and esr2b Expression in Female In Vivo Zebrafish Alzheimer Model.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Chronic Administration ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Neurobehavioral Protection by Prebiotic Formulations in a Scopolamine-Induced Cognitive Impaired Zebrafish Model.Life (Basel, Switzerland) · 2025Article
- Article
- Housing and husbandry factors affecting zebrafish novel tank test responses: a global multi-laboratory study.Lab animal · 2025Article
- Article
- Neuroprotective Potential ofBiomolecules · 2025Article
- Enhancement of Cognitive Benefits and Anti-Anxiety Effects ofAntioxidants (Basel, Switzerland) · 2025Article
- Behavioural variability and repeatability in adult zebrafish (Danio rerio) using the novel tank dive test.PloS one · 2025Article
- Alterations ofmicroPublication biology · 2025Article
- The synergistic extract ofFrontiers in aging neuroscience · 2025Article
- Anxiolytic and Antidepressant Effects ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- β-Carboline (FG-7142) modulates fear but not anxiety-like behaviour in zebrafish.Scientific reports · 2024Article
- Umbelliferone Ameliorates Memory Impairment and Enhances Hippocampal Synaptic Plasticity in Scopolamine-Induced Rat Model.Nutrients · 2023Article
- Zebrafish, a biological model for pharmaceutical research for the management of anxiety.Molecular biology reports · 2023Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scopolamine (hyoscine) is a muscarinic acetylcholine receptor antagonist that has traditionally been used to treat motion sickness in humans. However, studies investigating depressed and bipolar populations have found that scopolamine is also effective at reducing depression and anxiety symptoms. The potential anxiety-reducing (anxiolytic) effects of scopolamine could have great clinical implications for humans; however, rats and mice administered scopolamine showed increased anxiety in standard behavioural tests. This is in direct contrast to findings in humans, and complicates studies to elucidate the specific mechanisms of scopolamine action. The aim of this study was to assess the suitability of zebrafish as a model system to test anxiety-like compounds using scopolamine. Similar to humans, scopolamine acted as an anxiolytic in individual behavioural tests (novel approach test and novel tank diving test). The anxiolytic effect of scopolamine was dose dependent and biphasic, reaching maximum effect at 800 µM. Scopolamine (800 µM) also had an anxiolytic effect in a group behavioural test, as it significantly decreased their tendency to shoal. These results establish zebrafish as a model organism for studying the anxiolytic effects of scopolamine, its mechanisms of action and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.